Use of High-Dose-Rate Brachytherapy in the Management of Locally Recurrent Rectal Cancer

Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, USA.
Diseases of the Colon & Rectum (Impact Factor: 3.75). 08/2003; 46(7):895-9. DOI: 10.1097/01.DCR.0000075320.52257.25
Source: PubMed


Locally recurrent rectal cancer is associated with poor quality of life and has justified aggressive surgical and adjuvant approaches to control the disease. This study was designed to evaluate the use of fractionated perioperative high-dose-rate brachytherapy in association with wide surgical excision (debulking). Our hypothesis is that this combined therapy can help control locally recurrent rectal cancer.
Patients with biopsy-proven locally recurrent rectal cancer that could not be completely removed surgically were considered candidates for this procedure. All patients had abdominal exploration, aggressive tumor debulking, and placement of afterloading brachytherapy catheters. Patients underwent simulation on postoperative Day 3 and received 1,200 to 2,500 (mean, 1,888) cGy of fractionated high-dose-rate brachytherapy between postoperative Days 3 and 5. All patients had involvement of the lateral pelvic sidewall and/or the sacrum.
Twenty-seven patients (18 males) aged 32 to 79 years underwent therapy. Follow-up ranged from 18 to 93 (mean, 50) months and was available in 27 patients. Ten patients (37 percent) were alive at the time of this report. Nine patients are without evidence of disease. Five patients (18 percent) died of non-cancer-related causes without evidence of recurrent disease. Five complications potentially related to treatment (3 abscesses, 2 fistulas) occurred in five patients.
High-dose radiation brachytherapy delivers high-dose, highly controlled, focused radiation to specific sites of disease, thereby minimizing injury to normal tissues. The results in this series suggest increased local control, better palliation, and increased salvage of patients.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Of patients with newly diagnosed colorectal cancer who will undergo surgery with curative intent as part of their treatment, approximately 5–12% will have tumors that have spread beyond the anatomic landmarks of a standard resection and have invaded adjacent organs or structures.1–3 The goal of surgery in such cases is a wide, en bloc resection of the tumor and any involved adjacent organ or structure. Of patients who undergo resection with curative intent and receive adjuvant therapy, between 7 and 33% develop isolated local or regional recurrences.4,5 In up to 20% of these recurrences, resection can be curative.4,6,7
  • Source
    Jie Wu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We study co-H-maps from a suspension to the suspension of the projective plane and provide examples of non-suspension 3-cell co-H-spaces.
    Topology and its Applications 09/2002; 123(3-123):547-571. DOI:10.1016/S0166-8641(01)00221-8 · 0.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the feasibility, efficacy and toxicity of High Dose Rate Intraluminal Brachytherapy (HDRILB) in combination with External Beam Radiotherapy (EBR) used in the palliative treatment of selected patients of adenocarcinoma rectum. A prospective pilot study. The study was conducted at the Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar. The study started in April 1996 and the patients accrual was completed in June 1997. The patients with adenocarcinoma rectum, who refused surgery, had contraindications for surgery or had advanced and/or metastatic disease were treated with HDRILB in combination with external beam radiotherapy (EBR). The apparatus used for HDRILB was Ralstron 20B remote afterloading unit with 60Co stepping source. Indigenously designed rectal applicators were used. The EBR was delivered through Pheonix 60Co teletherapy machine (Theratron AECL). The data for symptom burden and symptomatic relief was analyzed by applying Likert's method of summated scales. Data was analyzed after one week and at the end of the treatment. After one week of treatment, the relief in pain and bleeding per rectum (P/R) was 97%. Excellent palliation was achieved at the end of the treatment when perineal pain and bleeding P/R were relieved in 100%, discharge P/R in 87% and tenesmus in 93% of the cases. The use of HDRILB in combination with EBR can provide quick relief of symptoms in selected patients of adenocarcinoma rectum. This combination has an excellent palliative value because of its effectiveness, acceptable toxicity and overall short treatment duration.
    Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 12/2003; 13(11):633-6. · 0.35 Impact Factor
Show more